Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Albert David's 3-Year RORE % for the quarter that ended in Mar. 2026 was -100.54%.
The industry rank for Albert David's 3-Year RORE % or its related term are showing as below:
NSE:ALBERTDAVD's 3-Year RORE % is ranked worse than 91.01% of 945
companies
in the Drug Manufacturers industry
Industry Median: 3.09
vs NSE:ALBERTDAVD: -100.54
Albert David (NSE:ALBERTDAVD) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Albert David 3-Year RORE % Related Terms
Albert David 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Albert David's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Albert David's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Albert David 3-Year RORE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Albert David's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Albert David's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Albert David (NSE:ALBERTDAVD) has a 3-Year RORE % of -100.54 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Albert David and its competitors. According to the industry distribution chart, Albert David ranks #860 out of 945 companies in the Drug Manufacturers industry, placing it in the top 91%.
Is Albert David's 3-Year RORE % too high?
Albert David's current 3-Year RORE % is -100.54. Based on the distribution chart, Albert David ranks #860 out of 945 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Albert David has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Albert David's 3-Year RORE % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Albert David ranks #860 out of 945 companies for 3-Year RORE %. This places Albert David in the lower half of its industry. The industry median 3-Year RORE % is 3.09. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Drug Manufacturers company?
The median 3-Year RORE % among Drug Manufacturers companies is 3.09, based on 945 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Albert David and its competitors. For the Drug Manufacturers industry, the median 3-Year RORE % is 3.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Albert David's current 3-Year RORE % is -100.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Albert David stock overvalued right now?
Based on GuruFocus' analysis, Albert David (NSE:ALBERTDAVD) is currently considered Fairly Valued. The stock's GF Value™ is ₹818.27, compared to a current price of ₹822.85 — trading 0.6% above its estimated fair value. The current 3-Year RORE % is -100.54. Albert David's overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Albert David (NSE:ALBERTDAVD), the current 3-Year RORE % is -100.54 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Albert David (NSE:ALBERTDAVD) Overvalued in 2026?
Based on GuruFocus' analysis, Albert David stock appears to be overvalued.
The current stock price of ₹822.85 is trading 0.6% above its estimated GF Value™ of ₹818.27.
GuruFocus considers Albert David to be Fairly Valued.
Key valuation signals for NSE:ALBERTDAVD:
3-Year RORE %: -100.54
GF Value™: ₹818.27 vs. price of ₹822.85 (0.6% above fair value)
No single metric tells the full story. See the NSE:ALBERTDAVD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Albert David Ltd is engaged in the manufacturing and trading of pharmaceutical products. The company offers products such as pharmaceutical formulations, infusion solutions, herbal dosage forms, and bulk drugs. Its formulation product covers parenteral, oral, enteral, topical agents, and vision care solutions. The company exports its product to regions like Latin America, Southeast Asia, and a few African countries. The Company is only engaged in the manufacturing of pharmaceutical products, ipso facto, one reportable segment.
73GF Score
Get the complete analysis for NSE:ALBERTDAVD
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ALBERTDAVD has been successfully added to your 
